Online citations, reference lists, and bibliographies.
← Back to Search

Current Strategies For The Delivery Of Therapeutic Proteins And Enzymes To Treat Brain Disorders.

J. Duskey, D. Belletti, F. Pederzoli, M. A. Vandelli, F. Forni, B. Ruozi, G. Tosi
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Brain diseases and injuries are growing to be one of the most deadly and costly medical conditions in the world. Unfortunately, current treatments are incapable of ameliorating the symptoms let alone curing the diseases. Many brain diseases have been linked to a loss of function in a protein or enzyme, increasing research for improving their delivery. This is no easy task due to the delicate nature of proteins and enzymes in biological conditions, as well as the many barriers that exist in the body ranging from those in circulation to the more specific barriers to enter the brain. Several main techniques are being used (physical delivery, protein/enzyme conjugates, and nanoparticle delivery) to overcome these barriers and create new therapeutics. This review will cover recently published data and highlights the benefits and deficits of possible new protein or enzyme therapeutics for brain diseases.
This paper references
10.1038/srep14144
RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies
W. Acosta (2015)
10.1111/jnc.13533
Low‐dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA
B. King (2016)
10.1074/jbc.M114.557439
A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis*
B. Spencer (2014)
10.1016/j.pharmthera.2014.05.009
Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
P. Calias (2014)
10.1371/journal.pone.0156452
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Marika Salvalaio (2016)
10.1007/s10989-014-9433-9
Angiopep-2-Mediated Delivery of Human Manganese Superoxide Dismutase in Brain Endothelial Cells and its Protective Effect Against Oxidative Stress
Warawan Eiamphungporn (2014)
10.1016/j.ymgme.2015.03.002
Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
H. Beard (2015)
10.1016/j.addr.2008.03.005
Microbubbles in ultrasound-triggered drug and gene delivery.
S. Hernot (2008)
10.1021/mp300495e
Diffusion of macromolecules in the brain: implications for drug delivery.
Daniel J. Wolak (2013)
The introduction of enzymes into cells by means of liposomes.
M. Finkelstein (1978)
10.2147/IJN.S93571
Carbon nanospheres mediated delivery of nuclear matrix protein SMAR1 to direct experimental autoimmune encephalomyelitis in mice
S V Chemmannur (2016)
10.1016/j.jconrel.2012.04.044
Challenges in drug delivery to the brain: nature is against us.
S. Krol (2012)
10.3171/2014.12.FOCUS14758
Therapeutic strategies to improve drug delivery across the blood-brain barrier.
T. Azad (2015)
10.1016/j.ejps.2012.12.006
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.
Stephanie D. Steichen (2013)
10.1016/S1461-5347(98)00110-2
Dynamic in vitro modeling of the blood–brain barrier: a novel tool for studies of drug delivery to the brain
Damir Janigro (1999)
10.1016/j.neurobiolaging.2014.10.006
The N-terminal region of myelin basic protein reduces fibrillar amyloid-β deposition in Tg-5xFAD mice
Ming-Hsuan Ou-Yang (2015)
10.1016/j.jconrel.2012.09.007
Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
Eun-joo Park (2012)
10.1038/mt.2013.267
Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain.
Yu Meng (2014)
10.1016/j.nbd.2009.07.028
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
R. Gabathuler (2010)
10.1016/j.addr.2011.12.006
Polymeric nanoparticles for drug delivery to the central nervous system.
T. Patel (2012)
10.1021/mp500241y
Clathrin-Mediated Endocytosis Is Impaired in Type A–B Niemann–Pick Disease Model Cells and Can Be Restored by ICAM-1-Mediated Enzyme Replacement
J. Rappaport (2014)
10.1016/j.jbiotec.2016.01.015
A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment.
Paul A Gramlich (2016)
10.1038/mt.2014.13
From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery.
I. Mäger (2014)
10.1016/j.ymgme.2015.05.005
Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.
J. Lu (2015)
10.4172/2157-7439.S4-003
Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease.
Y. Zhao (2011)
10.2147/IJN.S52236
Nanoscale drug delivery systems and the blood–brain barrier
R. Alyautdin (2014)
10.1016/J.PROGPOLYMSCI.2016.09.006
Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches
S. Mignani (2017)
10.1021/jm800156z
Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries.
Morteza Malakoutikhah (2008)
10.1002/wnan.73
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.
S. Muro (2010)
10.3109/1061186X.2015.1029930
Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor
Tarun Garg (2015)
10.1038/mt.2014.129
ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
B. Spencer (2014)
10.1016/j.biotechadv.2015.02.004
BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
H. Peluffo (2015)
10.1021/nn5018523
Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier.
M. Bramini (2014)
10.1128/CMR.00007-10
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
R. Nau (2010)
10.1016/j.addr.2011.11.010
Modern methods for delivery of drugs across the blood-brain barrier.
Y. Chen (2012)
10.1016/j.neuron.2015.11.024
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Y. J. Y. Zuchero (2016)
10.1038/jcbfm.2012.209
Nanoparticles for Targeted Delivery of Antioxidant Enzymes to the Brain after Cerebral Ischemia and Reperfusion Injury
Xiang Yun (2013)
10.3233/nre-2007-22502
The impact of traumatic brain injuries: a global perspective.
A. Hyder (2007)
10.1016/j.nano.2016.01.004
Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles.
N. Serna (2016)
10.1016/j.jconrel.2011.08.017
Transport of drugs across the blood-brain barrier by nanoparticles.
Stefanie Wohlfart (2012)
10.1111/j.1471-4159.2011.07337.x
Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain
A. Boutajangout (2011)
10.1002/jnr.23423
Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)
M. Katz (2014)
10.1523/JNEUROSCI.4785-13.2014
Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A
A. Böckenhoff (2014)
10.1039/c6cs00076b
Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery.
Benjamí Oller-Salvia (2016)
10.1021/mp500258p
Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells
R. Boado (2014)
10.1371/journal.pone.0052925
Targeted Delivery of GDNF through the Blood–Brain Barrier by MRI-Guided Focused Ultrasound
F. Wang (2012)
10.1016/j.ymgme.2013.09.008
High-dose enzyme replacement therapy in murine Hurler syndrome.
L. Ou (2014)
10.1016/j.jconrel.2015.03.033
Exosomes as drug delivery vehicles for Parkinson's disease therapy.
M. Haney (2015)
10.1016/J.ULTRASMEDBIO.2004.08.002
Augmentation of cardiac protein delivery using ultrasound targeted microbubble destruction.
R. Bekeredjian (2005)
10.2147/IJN.S61288
Current approaches to enhance CNS delivery of drugs across the brain barriers
C. Lu (2014)
10.2147/IJN.S54750
Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood–brain barrier
M. Chaturvedi (2014)
10.1021/mp500046f
In vitro models of the blood-brain barrier for the study of drug delivery to the brain.
I. Wilhelm (2014)
10.1073/pnas.1416660111
Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB
Shih-hsin Kan (2014)
10.2147/IJN.S47129
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
H. Nehoff (2014)
10.1016/j.biomaterials.2013.11.001
Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Hong Jai Lee (2014)
10.1016/j.mcn.2015.03.001
Epidemiology of mild traumatic brain injury and neurodegenerative disease
Raquel C Gardner (2015)
10.1016/j.jconrel.2015.02.012
Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease.
M. Rotman (2015)
10.1038/nrd4363
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
S. Mitragotri (2014)
10.1016/j.actbio.2014.09.037
Biocompatibility of a coacervate-based controlled release system for protein delivery to the injured spinal cord.
Britta Rauck (2015)
10.1039/c6tb01387b
Delivery of an active lysosomal enzyme using GNeosomes.
K. Hamill (2016)
10.1016/j.critrevonc.2015.10.015
Nanoparticle-siRNA: A potential cancer therapy?
Samuel Wang Sherng Young (2016)
10.1186/s13024-015-0043-6
A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
B. Spencer (2015)
10.4137/PMC.S13384
Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier
John L. Mikitsh (2014)
10.1186/1743-8977-7-3
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
Sonu Bhaskar (2009)
10.18632/oncotarget.13243
Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro
J. Ma (2016)
10.1097/NEN.0b013e3182345e46
A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease
J. S. Miners (2011)
10.1016/j.ultras.2008.04.004
Progress and problems in the application of focused ultrasound for blood-brain barrier disruption.
N. Vykhodtseva (2008)
10.1155/2014/869269
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
R. Upadhyay (2014)
10.1016/j.addr.2013.08.008
Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
J. Kreuter (2014)
10.1016/j.apsb.2016.04.001
Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides
Tingting Lin (2016)
10.1016/J.YMGME.2006.12.012
Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
P. Dickson (2007)
10.1016/j.addr.2011.11.002
Intranasal delivery of biologics to the central nervous system.
Jeffrey J Lochhead (2012)
10.1038/nrd1662
Healing sound: the use of ultrasound in drug delivery and other therapeutic applications
S. Mitragotri (2005)
10.1073/pnas.1008025107
Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice
Teppei Fujikawa (2010)
10.1126/SCIENCE.285.5433.1569
In vivo protein transduction: delivery of a biologically active protein into the mouse.
S. Schwarze (1999)
10.1007/s13277-015-4681-7
A novel dual-targeted ultrasound contrast agent provides improvement of gene delivery efficiency in vitro
Jinfeng Xu (2015)
10.1002/cpt.18
Targeted delivery of protein and gene medicines through the blood–brain barrier
W. Pardridge (2015)
10.1371/journal.pone.0030341
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
P. Calias (2012)
Nanopartículas poliméricas de administración intranasal para la liberación de activos en el sistema nervioso central
Mª del Pilar García Corvillo (2016)
10.1007/s12264-016-0092-z
Exosomes in Parkinson’s Disease
Xiaoqing Wu (2016)
10.3390/pharmaceutics6040557
Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood–Brain Barrier
Julia V. Georgieva (2014)
Drug delivery to the central nervous system: a review.
A. Misra (2003)
10.1016/j.expneurol.2014.09.008
Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods
N. Marshall (2015)
10.1016/j.ddtec.2016.07.007
Ultrasound-mediated drug delivery to the brain: principles, progress and prospects.
A. Dasgupta (2016)
10.2217/nnm.16.15
Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis.
I. Posadas (2016)
10.1385/1-59259-419-0:209
In situ brain perfusion technique.
Q. Smith (2003)
10.1371/journal.pone.0106867
GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson's Disease Mouse Model
Y. Zhao (2014)
10.1517/17425247.5.2.155
Polymeric nanoparticles for the drug delivery to the central nervous system
G. Tosi (2008)
10.1016/j.ymgme.2014.09.004
Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
Brian R Vuillemenot (2015)
10.1016/j.jneumeth.2015.11.027
Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS
Abhilash P. Appu (2016)
10.3791/2968
Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice.
Jacqueline J. Glascock (2011)
10.1038/ncomms9244
dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis
Sangho Lim (2015)
10.1038/nbt.3330
Principles of nanoparticle design for overcoming biological barriers to drug delivery
E. Blanco (2015)
10.1038/mt.2013.273
Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers.
Neha Kohli (2014)
10.1021/cr200472g
Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.
S. Krol (2013)
10.1016/j.jconrel.2015.06.002
PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
C. Fornaguera (2015)
10.1016/j.cbpa.2013.03.023
Bispecific antibodies for delivery into the brain.
Ryan J Watts (2013)
10.1002/cmdc.201300575
‘À la Carte’ Peptide Shuttles: Tools to Increase Their Passage across the Blood–Brain Barrier
Morteza Malakoutikhah (2014)
10.1002/jps.23974
Protein nanoparticles for intracellular delivery of therapeutic enzymes.
L. H. Estrada (2014)
10.1016/j.mcn.2015.03.012
Neurological consequences of traumatic brain injuries in sports
H. Ling (2015)
10.1016/J.JDDST.2015.07.007
The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system
G. Tosi (2016)
10.1016/j.biotechadv.2014.11.005
Synthetic fusion protein design and applications.
K. Yu (2015)
10.1208/s12249-014-0143-6
Nanoparticle Ligand Presentation for Targeting Solid Tumors
J. Duskey (2014)
10.1073/pnas.1203534109
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain
R. E. Cannon (2012)
10.1016/j.jconrel.2016.01.017
Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model.
Yingzheng Zhao (2016)
10.3109/1061186X.2013.847098
Brain delivery of proteins via their fatty acid and block copolymer modifications
X. Yi (2013)
10.1016/j.ymgme.2014.08.009
Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Y. B. Sohn (2015)
10.1002/emmm.201202083
A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
N. C. Sorrentino (2013)
10.1016/j.ymgme.2011.06.018
Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
Brian R Vuillemenot (2011)
10.1186/1477-3155-9-55
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
A. Mahapatro (2011)
10.1021/nl404360k
Dual-Porosity Hollow Nanoparticles for the Immunoprotection and Delivery of Nonhuman Enzymes
Inanc Ortac (2014)
10.1016/j.addr.2011.10.007
Nanotechnological advances for the delivery of CNS therapeutics.
H. L. Wong (2012)
10.1016/j.jconrel.2014.06.017
Agile delivery of protein therapeutics to CNS.
X. Yi (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar